Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional-dose IPV delivery by intradermal needle-free devices versus standard full-dose IPV
ACTRN12612000482864Phase 4Not yet recruiting
- Sponsor
- World Health Organization
- Start
- Sep 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trivalent inactivated polio vaccine in poliomyelitis (5 arms), sponsored by World Health Organization. Primary endpoint: Seroconversion or antibody boost at Day 28. Planned start Sep 2012; status: not yet recruiting.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on ACTRN12612000482864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000482864.